ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2008
Experimental therapeutics for dystonia.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Multidimensional structural analyses revealed a correlation between thalamic atrophy and white matter degeneration in idiopathic dystonia.Brain communications · 2025Article
- Phenotypic Variability in Acquired and Idiopathic Dystonia.Movement disorders clinical practice · 2023Article
- A single-center real-life study on the use of medical cannabis in patients with dystonia.Frontiers in neurology · 2023Article
- The Anatomical Basis for Dystonia: The Motor Network Model.Tremor and other hyperkinetic movements (New York, N.Y.) · 2017Review
- Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury.Acta neuropathologica communications · 2016Article
- Tetrabenazine: Spotlight on Drug Review.Annals of neurosciences · 2016Review
- Clinimetric testing of the comprehensive cervical dystonia rating scale.Movement disorders : official journal of the Movement Disorder Society · 2016Article
- Dystonia and Paroxysmal Dyskinesias: Under-Recognized Movement Disorders in Domestic Animals? A Comparison with Human Dystonia/Paroxysmal Dyskinesias.Frontiers in veterinary science · 2015Review
- The New Classification System for the Dystonias: Why Was it Needed and How was it Developed?Movement disorders clinical practice · 2014Article
- Dystonia as a network disorder: what is the role of the cerebellum?Neuroscience · 2014Review
- Designing clinical trials for dystonia.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Review
- The focal dystonias: current views and challenges for future research.Movement disorders : official journal of the Movement Disorder Society · 2013Review
- Invertebrate models of dystonia.Current neuropharmacology · 2013Article
- The functional neuroanatomy of dystonia.Neurobiology of disease · 2011Review
- Increased sensorimotor network activity in DYT1 dystonia: a functional imaging study.Brain : a journal of neurology · 2010Article
- Treatment strategies for dystonia.Expert opinion on pharmacotherapy · 2010Review
- The basal ganglia and cerebellum interact in the expression of dystonic movement.Brain : a journal of neurology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Dystonia is a neurological syndrome characterized by excessive involuntary muscle contractions leading to twisting movements and unnatural postures. It has many different clinical manifestations, and many different causes. More than 3 million people worldwide suffer from dystonia, yet there are few broadly effective treatments. In the past decade, progress in research has advanced our understanding of the pathogenesis of dystonia to a point where drug discovery efforts are now feasible. Several strategies can be used to develop novel therapeutics for dystonia. Existing therapies have only modest efficacy, but may be refined and improved to increase benefits while reducing side effects. Identifying rational targets for drug intervention based on the pathogenesis of dystonia is another strategy. The surge in both basic and clinical research discoveries has provided insights at all levels, including etiological, physiological and nosological, to enable such a targeted approach. The empirical approach to drug discovery, whereby compounds are identified using a nonmechanistic strategy, is complementary to the rational approach. With the recent development of multiple animal models of dystonia, it is now possible to develop assays and perform drug screens on vast numbers of compounds. This multifaceted approach to drug discovery in dystonia will likely provide lead compounds that can then be translated for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.